Abstract
We designed liposomes dually functionalized with ApoE-derived peptide (mApoE) and chlorotoxin (ClTx) to improve their blood-brain barrier (BBB) crossing. Our results demonstrated the synergistic activity of ClTx-mApoE in boosting doxorubicin-loaded liposomes across the BBB, keeping the anti-tumour activity of the drug loaded: mApoE acts promoting cellular uptake, while ClTx promotes exocytosis of liposomes.
Introduction
The blood-brain barrier (BBB) remains a formidable obstacle in neuro-oncology, effectively blocking approximately 98% of small-molecule drugs and nearly all large-molecule therapeutics from reaching the brain parenchyma. While liposomal carriers offer a promising delivery vehicle, single-ligand targeting strategies (such as using the mApoE peptide alone) often fail to achieve significant clinical concentrations, typically reaching less than 0.3% of the injected dose in animal models. The primary bottleneck is not merely cellular entry into the endothelial lining but the subsequent exit (transcytosis) into the brain tissue.
Methodology and Characterization
To address this, we synthesized liposomes composed of cholesterol and sphingomyelin, loaded with the anti-cancer drug doxorubicin (DOX) via a remote-loading technique. These liposomes were dually functionalized with two peptides: mApoE, which triggers LDL-receptor-mediated endocytosis, and Chlorotoxin (ClTx), a scorpion venom-derived peptide with high affinity for glioma cells.
The physical characteristics of these nanocarriers were verified using Cryo-Transmission Electron Microscopy (Cryo-TEM), which revealed the characteristic morphology of the drug-loaded vesicles.
The transport efficiency was evaluated using an in vitro human BBB model (hCMEC/D3 cells) and monitored via Transendothelial Electrical Resistance (TEER) to ensure barrier integrity.
Results and the "Dual-Key" Mechanism
The dually functionalized liposomes (CADOX-LIP) demonstrated a remarkable 30-fold increase in BBB crossing compared to non-functionalized controls. Crucially, CADOX-LIP outperformed single-ligand systems, being 3 times more effective than mApoE-only liposomes and 10 times more effective than ClTx-only versions.
Molecular Dynamics Simulations (MDS) and experimental assays revealed a "division of labor" between the two peptides. While mApoE facilitates the initial apical uptake, ClTx appears to promote the basolateral egress (exocytosis), possibly through interactions with Annexin A2. Interestingly, the two peptides exhibit electrostatic repulsion on the liposome surface; this weak interaction prevents them from masking each other, ensuring both remain available for receptor binding.
Conclusion
This "dual-key" approach successfully bypasses the transcytosis bottleneck. In co-culture models with U87 glioblastoma cells, the transported liposomes reduced cancer cell viability by 76.6%, confirming that the therapeutic cargo remains active. Future work will focus on in vivo validation to determine if this synergistic strategy can overcome the historical 0.3% brain-delivery ceiling.
Summary updated